🙏This is personal🙏

📜Your people have always been servants: Internalised #Racism in #AcademicMedicine

🗣️'Instead of proving our worth, we should focus on knowing our worth'

Huge thanks✍️co-author mentor Christopher Buckley & The Lancet for sharing my story
thelancet.com/journals/lance…

Check it out and come visit our trial in progress poster! ➡️ ash.confex.com/ash/2022/webpr… Craig Hofmeister Pritesh Patel #mmsm #bmtsm #oncopharm

MM and BMT folks: did you know there is 500% variation in high dose melphalan plasma exposure among MM patients undergoing ASCT? How is it acceptable that we deliver such an extremely important drug in such an unreliable way? Test dose strategies have failed but....

#Tandem22 Have you ever wondered about conducting a systematic review in #BMTsm and cellular therapy and didn’t know where to start? Come join us and listen to Linda J Burns, MD Mohamed Kharfan-Dabaja, MD, MBA and me at the ASTCT Spotlight Session Saturday morning 645am in Rm 155D tandem.confex.com/tandem/2022/me…

#Tandem22 Despite our best efforts, disparities still exist in access to #BMTsm and cellular therapies, Eneida Nemecek 🇵🇷 from OHSU Knight Cancer Institute Dr Staci Arnold from Emory University and Dr Madbouly from @BTMPublicPolicy will be discussing what they are and how they affect our pts 👇🏽

Excited to disseminate such important work on inequities in #myeloma supportive care with @JennyGuadamuz Karen Sweiss Pritesh Patel Manni Mohyuddin

Pritesh Patel Nico Gagelmann CIBMTR EBMT Patient Advocacy Committee VJHemOnc A/Prof Nada Hamad LABMT Andres Gomez Anna Sureda andreugusi @TheEBMT Can’t agree more Pritesh Patel. Companies should ensure that sites caring for high proportion of racial/ethnic minorities and/or socio-economically disadvantaged population are give equal consideration while opening trials and rollout of approved products.

Significant but unfortunately not surprising difference in recipients background of CART in CIBMTR presented at #EBMT22 . Probably just the tip of the iceberg and supporting the notion that CART, despite all hopes, may be THE accelerator for already existing inequalities.

Diversity is chronically lacking in clinical trials submitted to the U.S. FDA for drug approval, so the agency launched a 5 year Action Plan in 2015. In @health_affairs we @sloan_kettering found no improvement in trial representativeness per 'Snapshots' 1/3 healthaffairs.org/doi/10.1377/hl…

How to spot the real introverts. nyer.cm/7ehjCzO

Turning it on its head... we know PK of drugs influence PD but With Mabs, PD affects PK. Could baseline sBCMA and IgG levels help us predict who will have higher ADC exposure and ocular tox? #ASH21 #mmsm Pritesh Patel

Such a huge undertaking! The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets | Nature Cancer nature.com/articles/s4301…

This… #ASH21

Karen Sweiss #ASH21 great data on COVID vax hesitancy in blood cancer pts. Issues are trust (race/gender) and social media misinformation. This is a big health risk for our patients. To educate we must address these👇A #IntersectionalMed lens is critical. #ASHKudos Leukaemia Foundation

➡️You can check suggestions for change JCO Oncology Practice
ascopubs.org/doi/full/10.12…
➡️Check solutions
➡️Most important we need to make sure trials are open in centers that serve African Americans (availability is the key)

#ASH21 Oral: PS-matched comparison of axi-cel & tisa-cel in a cohort of R/R DLBCL (DESCAR-T registry).
axi-cel n=321, tisa-cel n=183
✔️CRR, ORR, PFS higher w/ axi-cel
✔️⬆️ NT w/ axi-cel
✔️No diff in DOR
✔️No diff in OS
Emmanuel Bachy Mohamad Mohty The EBMT Miguel Perales M.D. ASTCT

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma | ⁦Frederick L. Locke⁩ NEJM Proud to have contributed to this practice changing study #ASH21 #CARTcells nejm.org/doi/full/10.10…